State R&D Credits · Brief · Working level
Connecticut's R&D credits: two computations and a cash-out for small companies
Connecticut offers both a non-incremental and an incremental research credit against the corporation business tax, with annual usage limits — and lets qualifying small companies exchange unused credits for cash at 65 cents on the dollar.
Connecticut runs two research credits side by side against its corporation business tax: a non-incremental credit computed on total Connecticut research and experimental expenditures at tiered rates, and an incremental credit equal to 20% of the excess of current-year Connecticut R&D spending over the prior year (as of mid-2026). Both are nonrefundable — but Connecticut is one of the few states with an exchange provision, letting qualifying small companies cash out unused credits at 65% of face value. As with every state in this cluster, rates and thresholds move legislatively; confirm current law with the Connecticut Department of Revenue Services before relying on any figure here.
How the two credits work
The non-incremental credit applies to a company's full Connecticut research and experimental expenditure base — not just the increase — at rates that step up with spending, from the low single digits for modest budgets toward 6% for the largest spenders; small companies get a flat rate at the top of that band regardless of spending level (as of mid-2026; the Connecticut Department of Revenue Services publishes the current schedule). The expenditure definition tracks the federal Section 174 concept of research and experimental costs rather than the narrower Section 41 QRE categories, which means some costs excluded from the federal credit can count here.
The incremental credit is simpler: 20% of the excess of current-year Connecticut R&D expenses over the prior year's. A company with flat spending gets nothing from this leg; a company scaling its Connecticut lab gets both credits on the growth.
Connecticut then imposes usage limits that matter more than the headline rates. Only a fraction of the non-incremental credit earned in a year may be claimed in that year (historically one-third), and total credits can offset only a portion of the corporation business tax — a percentage cap that the legislature has adjusted repeatedly. Unused amounts carry forward, with the non-incremental credit carrying until used and the incremental credit for 15 years (as of mid-2026).
The 65% exchange for small companies
The distinctive feature is the exchange provision. A qualifying small business — eligibility keys to a gross-income ceiling set by statute — that cannot use research credits because it lacks sufficient tax liability may exchange them with the state for a cash payment equal to 65% of the credit's value. For a pre-revenue biotech or software company running losses, this converts a paper asset into working capital, at a 35% haircut.
The table compares the practical value of a $100,000 earned credit under each monetization path (as of mid-2026; illustrative).
| Path | Who uses it | Cash value of $100,000 credit |
|---|---|---|
| Offset corporation business tax | Profitable C corporations | $100,000, subject to annual usage caps |
| Carryforward | Companies expecting future liability | $100,000 nominal, discounted by time |
| 65% exchange | Qualifying small companies with no liability | $65,000 now |
Who benefits, and the traps
The credits fit C corporations doing research physically in Connecticut — the situs rule applies, so multistate companies must source wages, supplies, and contract research to Connecticut activity. The exchange makes the state unusually attractive to loss-stage companies that qualify as small.
Two traps recur. First, entity type: the credits run against the corporation business tax, so pass-through entities generally cannot claim them — a startup organized as an LLC taxed as a partnership gets nothing, exchange included, and the fix (if worth it) is structural. Second, the usage caps: profitable companies modeling the credit at face value overstate the year-one benefit, because the one-third claiming rule and the liability-percentage cap stretch realization over years. Model the caps, not the headline.
Filing runs through the corporation business tax return with the applicable credit forms; the exchange requires its own election. Companies claiming both credits should build the computation from the same Connecticut-sourced expenditure workpapers used for the federal claim — the definitions overlap enough that one dataset, tagged by state, serves both. See how state credits differ for the general framework, and refundable and transferable state credits for how Connecticut's exchange compares to other states' cash-out routes.
Frequently asked questions
- Does Connecticut have an R&D tax credit?
- Yes. Connecticut offers two research credits against the corporation business tax: a non-incremental credit computed on total in-state research expenses at tiered rates, and an incremental credit on the increase in Connecticut research spending over the prior year. Both are nonrefundable, but qualifying small companies can exchange unused credits for a cash payment at 65% of value.
- Can Connecticut R&D credits be converted to cash?
- For small companies, yes. A qualifying small business — the statute keys eligibility to a gross-income ceiling — that cannot use its research credits because it has insufficient corporation business tax liability may exchange them with the state for a cash payment equal to 65% of the credit's value. Larger companies must carry credits forward instead.
- Do Connecticut's research credits apply to pass-through entities?
- Generally no. The credits apply against Connecticut's corporation business tax, so C corporations are the primary claimants. Pass-through owners generally cannot use them against personal income tax, which is a recurring surprise for LLC-taxed startups that assumed the exchange provision would apply to them.